[CAS NO. 20350-15-6] BrefeldinA

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [20350-15-6]

Catelog

HY-16592

Brand

MCE

CAS

20350-15-6

DESCRIPTION [20350-15-6]

Overview

MDL	MFCD00083258
Molecular Weight	280.36
Molecular Formula	C16H24O4
SMILES	O[C@@H]1C[C@]2([H])[C@@](/C=C/CCC[C@H](C)OC(/C=C/[C@H]2O)=O)([H])C1

For research use only. We do not sell to patients.

31 Publications Citing Use of MCE

Summary

Brefeldin A (BFA) is a lactone antibiotic and a specific inhibitor of protein trafficking . Brefeldin A blocks the transport of secreted and membrane proteins from endoplasmic reticulum to Golgi apparatus ^[1] ^[2] . Brefeldin A is also an autophagy and mitophagy inhibitor ^[3] . Brefeldin A is a CRISPR/Cas9 activator ^[5] . Brefeldin A inhibits HSV-1 and has anti-cancer activity ^[5] .

IC50 & Target

CRISPR/Cas9

HSV-1

In Vitro

Brefeldin A (BFA) treatment for 15 h or 40 h, causes dramatic swelling of the Endoplasmic Reticulum (ER) and shifts its localization to the periphery of normal rat kidney (NRK) cells. Prolonged Brefeldin A treatment results in marked disruption of the MT and actin cytoskeleton ^[1] . ADP-ribosylation of BARS is mediated by formation of a conjugate between Brefeldin A and ADPR. BARS shows BAC binding when incubated with the medium from the BFA-treated CD38 ⁺ HeLa cells ^[3] . Brefeldin A induces anchorage-independent cell death in MDA-MB-231 breast cancer cells, inhibits the formation of MDA-MB-231 colonies in 3D and 2D cultures and inhibits the migration and MMP 9 (Matrix Metallopeptidase 9) activity of MDA-MB-231 ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Appearance

Solid

Source

Penicillium

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 356.68 mM ; Need ultrasonic)

Ethanol : 11.11 mg/mL ( 39.63 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5668 mL	17.8342 mL	35.6684 mL
5 mM	0.7134 mL	3.5668 mL	7.1337 mL
10 mM	0.3567 mL	1.7834 mL	3.5668 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution
4.

Add each solvent one by one: 10% EtOH >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution
5.

Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution
6.

Add each solvent one by one: 10% EtOH >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (8.92 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

4H-Cyclopent[f]oxacyclotridecin-4-one, 1,6,7,8,9,11a,12,13,14,14a-decahydro-1,13-dihydroxy-6-methyl-, (1R,2E,6S,10E,11aS,13S,14aR)-

4H-Cyclopent[f]oxacyclotridecin-4-one, 1,6,7,8,9,11aβ,12,13,14,14aα-decahydro-1β,13α-dihydroxy-6β-methyl-

4H-Cyclopent[f]oxacyclotridecin-4-one, 1,6,7,8,9,11a,12,13,14,14a-decahydro-1,13-dihydroxy-6-methyl-, [1R-(1R*,2E,6S*,10E,11aS*,13S*,14aR*)]-

(1R,2E,6S,10E,11aS,13S,14aR)-1,6,7,8,9,11a,12,13,14,14a-Decahydro-1,13-dihydroxy-6-methyl-4H-cyclopent[f]oxacyclotridecin-4-one

Brefeldin A

Ascotoxin

Cyanein

Decumbin

Cyanaein

Nectrolide

Synergisidin

(+)-Brefeldin A

Brefeldin

NSC 107456

NSC 244390

NSC 56310

NSC 89671